METADATA
last updated: 2026-03-18 RT
file_name: _context-commentary_regulatory-reg-articles-misc.md
category: regulatory
subcategory: reg-articles-misc
gfile_url: https://docs.google.com/document/d/1xx-Q92DTu_8sfcmDy22CP438nNey_La1ak5oMeZR0Vo
words: 492
tokens: 736


CONTENT

## Context
This `regulatory/reg-articles-misc` subcategory collects a small number of higher-level reports and assessments related to FDA oversight of COVID-19 diagnostics. These files are third-party or government-produced documents that provide a broader perspective on the EUA process and diagnostic test validation during the pandemic.

The three documents are:
- `2021-10-08_FDA Report - EUA Assessment by Booze Allen`: An FDA-commissioned review of CDRH's COVID-19 test EUA response, covering how the FDA used templates, guidance updates, triage, and deprioritization to manage thousands of submissions. It includes priority recommendations around IT systems, staffing models, and a validation framework for future emergencies. This report predates the Omicron surge and the severe testing shortages that followed.
- `2022-07-01_FDA Report - FDAs Work to Combat the COVID-19 Pandemic`: A broad FDA overview summarizing cross-center actions on vaccines, therapeutics, diagnostics, supply chain, inspections, and regulatory science, with data current as of April 2022.
- `2021-01-18_Phillips and Dinakar - A Proposal for Increasing the Speed of Validating SARS-CoV-2 Diagnostic Tests`: A paper proposing three extensions to the EUA process for accelerating diagnostic test validation: structured (machine-readable) EUA data submissions, distributed FDA-directed CLIA-led validation, and building an open synthetic patient clinical specimen panel.

In addition, an AI-generated research report (`_AI_fda-eua-covid-retrospectives_post2022_report`) was created during archive preparation to identify post-2022 retrospectives, evaluations, and criticisms of the FDA's EUA process. That report catalogs sources from government oversight agencies (HHS OIG, GAO, FDA), legislative bodies, NGOs, professional associations, and academics, and may serve as a starting point for readers interested in pursuing the broader literature on EUA reform and pandemic preparedness policy.

### Archive Files Not Converted to Markdown
`2021-02-02_California Coronavirus Testing Task Force - COVID-19 Testing Task Force Laboratory List .xlsx`
`ACLA - FAQ on COVID test reporting requirements for CLIA labs.pdf`
`CLIA Related Links.docx`
`CLIA Related Links.pdf`


## Commentary
The Phillips and Dinakar proposal for structured, machine-readable EUA data submissions resonated with FloodLAMP's own experience navigating the EUA process. The idea that submissions could be standardized in a way that accelerates FDA review, reduces ambiguity for developers, and enables computational analysis of submission data is the kind of practical, systems-level reform that would likely have compounding benefits across future emergencies.

More broadly, the potential for AI to improve FDA processes around diagnostic test evaluation, guidance development, and emergency response has been a recurring theme throughout this archive (see commentary on the `regulatory/fda-townhalls` subcategory and the `regulatory/open-euas` subcategory). The scale and complexity of the COVID-19 testing response — thousands of EUA submissions, rapidly evolving guidance, variant-driven obsolescence — represent exactly the kind of problem where AI-assisted workflows could meaningfully reduce friction, increase objectivity, and greatly reduce the discretionary and unpredictable FDA EUA review process that was in place during the COVID pandemic. Imagine if those same AI evaluation systems were transparent, objective, open, and available to test developers, and had already been scrutinized by a broad base of researchers in industry and academia; that kind of infrastructure could dramatically unlock testing and improve outcomes.